Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 79
Selected: 0
NCT IDTitle
NCT02631642A Study of HMPL-689 in Healthy Volunteers
NCT05015608Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification
NCT03860532Phase I Clinical Trial in Healthy Male Volunteers
NCT02503033A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies
NCT02590952A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors
NCT03873532A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients
NCT02320409A Food Effect Phase I Study of the Sulfatinib in Healthy Subjects (HMPL-012)
NCT02976116A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer
NCT03223376A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)
NCT04755088Surufatinib Renal Impairment Study
NCT05173142A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors
NCT03128164A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed
NCT04322539A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer
NCT01805791A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis
NCT04849351Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
NCT02857998A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms
NCT05842525Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer
NCT01773018Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors
NCT02588170Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors
NCT04755075Surufatinib Hepatic Impairment Study
NCT03231501HMPL-813 in Treating Patients With Glioblastoma
NCT01955304Food Effect Study of Single Dose of Fruquintinib (HMPL-013) in Healthy Subjects
NCT02966171A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies
NCT05522738Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer
NCT01882764HMPL-004 Maintenance Treatment in Subjects With Mild to Moderate Ulcerative Colitis
NCT02897479A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer
NCT05318820A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers
NCT05511051A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy
NCT04557397Fruquintinib CYP3A Inhibitor and Inducer Study
NCT04372407A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy Subjects
NCT04923945Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients
NCT02691299A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer
NCT04645940Fruquintinib Food Effect and Proton Pump Inhibitor Study
NCT00659802Phase II Study of HMPL-004 in Patients With Ulcerative Colitis
NCT03251378A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers
NCT02415023A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer
NCT04923932Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients
NCT05015621A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma
NCT04290325HMPL-453 in Advanced Malignant Mesothelioma
NCT03951623The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients
NCT03860948A Pharmacokinetic and Bioequivalence Study of Savolitinib Tablets in Healthy Chinese Male Volunteers
NCT03778229Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
NCT02105129A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523
NCT03160833A Study of HMPL-453 in Patients With Advanced Solid Malignancies
NCT02614495Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma
NCT04169672Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors
NCT01985555Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors
NCT03977090Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer
NCT03483259To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers
NCT02601274Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor